TTRX logo

TTRX
Turn Therapeutics Inc

391
Mkt Cap
$101.29M
Volume
13,899.00
52W High
$26.50
52W Low
$2.57
PE Ratio
-25.98
TTRX Fundamentals
Price
$3.44
Prev Close
$3.43
Open
$3.35
50D MA
$3.92
Beta
1.44
Avg. Volume
20,210.85
EPS (Annual)
-$0.1318
P/B
173.13
Loading...
Loading...
News
all
press releases
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
Turn Therapeutics (NASDAQ:TTRX) executives outlined the company's focus on inflammatory skin disease and provided updates on its lead topical candidate, GX-03, during a presentation at an...
MarketBeat·20d ago
News Placeholder
More News
News Placeholder
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment...
Business Wire·1mo ago
News Placeholder
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief...
Business Wire·1mo ago
News Placeholder
Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated a "buy" rating and issued a $8.00 price target on shares of Turn Therapeutics in a report on Tuesday...
MarketBeat·2mo ago
News Placeholder
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced...
Business Wire·2mo ago
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Upgraded to "Strong-Buy" at D Boral Capital
D Boral Capital upgraded shares of Turn Therapeutics to a "strong-buy" rating in a research report on Monday...
MarketBeat·3mo ago
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Coverage Initiated at D. Boral Capital
D. Boral Capital assumed coverage on Turn Therapeutics in a research report on Monday. They set a "buy" rating and a $8.00 price target on the stock...
MarketBeat·3mo ago
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Director Purchases $33,945.92 in Stock
Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden bought 9,868 shares of Turn Therapeutics stock in a transaction that occurred on Monday, November 24th. The stock was...
MarketBeat·4mo ago
News Placeholder
Insider Buying: Turn Therapeutics (NASDAQ:TTRX) Director Buys 20,532 Shares of Stock
Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden acquired 20,532 shares of Turn Therapeutics stock in a transaction dated Friday, November 21st. The shares were bought at...
MarketBeat·4mo ago
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Releases Quarterly Earnings Results
Turn Therapeutics (NASDAQ:TTRX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter...
MarketBeat·4mo ago
<
1
2
...
>

Latest TTRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.